資源描述:
《血管緊張素受體拮抗劑聯(lián)合用藥治療高血壓患者的療效觀察》由會員上傳分享,免費在線閱讀,更多相關內容在工程資料-天天文庫。
1、血管緊張素受體拮抗劑聯(lián)合用藥治療高血壓患者的療效觀江蘇省泰興市張橋衛(wèi)生院225400【摘要】目的觀察血管緊張素受體拮抗劑(ARB)聯(lián)合β受體阻滯劑治療高血壓患者的臨床療效。方法選擇泰興市張橋衛(wèi)生院全科門診自2012年3月至2015年3月期間就診的100例高血壓患者,隨機分為觀察組和對照組,每組50例。觀察組采用ARB聯(lián)合β受體阻滯劑即纈沙坦和美托洛爾緩釋片聯(lián)合治療;對照組采用鈣拮抗劑(CCB)聯(lián)合β受體阻滯劑即氨氯地平聯(lián)合美托洛爾緩釋片。觀察和比較兩組治療后10周的收縮壓、舒張壓和心率變化情況以及癥狀改善情況。結果治療10周后,兩組收
2、縮壓、舒張壓和心率均較治療前丁降顯著,差異有統(tǒng)計學意義(P<0.05);觀察組治療10周后收縮壓、舒張壓與對照組比較,差異無統(tǒng)計學意義(P>0.05);但治療10周后心率和癥狀改善情況明顯優(yōu)于對照組,差異有統(tǒng)計學意義(P<0.05)。結論ARB聯(lián)合β受體阻滯劑治療高交感張力高血壓患者,具有安全有效、不良反應少的優(yōu)點,值得臨床推廣,尤其是在基層?!娟P鍵詞】高血壓;血管緊張素受體拮抗劑;β受體阻滯劑;鈣拮抗劑;心率;收縮壓;舒張壓[Abstract]ObjectiveToobservetheclinicaleffectofangiotensinre
3、ceptorblockers(ARB)combinedwithbetablockersinthetreatmentofhypertension.Methods100patientswithhypertensionfromMarch2015toMarch2012wererandomlydividedintoobservationgroupandcontrolgroup,50casesineachgroup.TheobservationgroupwastreatedwithARBcombinedwithabetablockerorvalsartanandmetopro
4、lolsustained-releasetabletscombinedtreatment;controlgroupwithcalciumantagonists(CCB)combinedwithabetablockeroramlodipinecombinedwithmetoprololsustained-releasetablets.Thechangesofsystolicbloodpressure,diastolicbloodpressure,heartrateandtheimprovementofsymptomswereobservedandcomparedbe
5、tweenthetwogroupsafter10weeksoftreatment.ResultsAfter10weeksoftreatment,thesystolicbloodpressure,diastolicbloodpressureandheartrateofthetwogroupsweresignificantlylowerthanthosebeforetreatment,thedifferencewasstatisticallysignificant(P<0.05);After10weeksoftreatment,thesystolicbloodp
6、ressureanddiastolicbloodpressureoftheobservationgroupwerecomparedwiththatofthecontrolgroup(P>0.05);Butafter10weeksoftreatment,heartrateandsymptomimprovementweresignificantlybetterthanthecontrolgroup,thedifferencewasstatisticallysignificant(P<0.05).ConclusionARBcombinedwithbetabl
7、ockersinthetreatmentofpatientswithhighbloodpressureandhypertension,hastheadvantagesofsafeandeffective,lessadversereactions,itisworthyofclinicalpromotion,especiallyatthegrassrootslevel.【Keywords】Hypertension;Angiotensinreceptorblockers;Betablockers;Calciumantagonists;Heartrate;Systolic
8、blood